title: Dioxin causes ventral prostate agenesis by disrupting dorsoventral patterning in developing mouse prostate.
abstract: Prostate ductal development is initiated by androgen-dependent signals in fetal urogenital sinus (UGS) mesenchyme that stimulate prostatic bud formation in UGS epithelium. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD, 5 microg/kg maternal dose) inhibited ventral and dorsolateral but not anterior prostatic budding. We sought to determine which stage of budding, specification or initiation, was inhibited. Ventral prostatic bud formation was maximally inhibited when TCDD exposure spanned E15.5-16.5 and dorsolateral prostatic bud formation when it spanned E14.5-15.5. Because ventral and dorsolateral buds are specified at these times, TCDD impaired bud specification. We hypothesized that TCDD inhibited ventral bud specification by forming a continuous smooth muscle barrier between UGS mesenchyme and epithelium in the ventral prostatic UGS region, blocking mesenchymal-epithelial signaling, but no such barrier was found. We hypothesized that increased aryl hydrocarbon receptor (AHR) signaling in ventral and dorsolateral UGS increased their sensitivity to TCDD, but levels of AHR nuclear translocator (ARNT) protein, Ahr mRNA, and AHR-dependent gene expression were not higher than in anterior UGS where budding was unaffected. However, we identified overlapping expression of Ahr, ARNT, and AHR-induced transcripts in the periprostatic mesenchyme which intimately contacts UGS epithelium where buds are specified. This was considered the putative TCDD site of action in the UGS for inhibition of ventral and dorsolateral prostatic bud specification. Thus, hyperactivation of AHR signaling appears to disrupt dorsoventral patterning of the UGS, reprogramming where prostatic buds are specified, and prostate lobes are formed. Disrupted axial patterning provides a new paradigm for understanding how in utero TCDD exposure causes ventral prostate agenesis and may shed light on how TCDD impairs development of other organs.
authors.affiliation: School of Pharmacy, University of Wisconsin, Madison, Wisconsin 53705, USA.
authors.forename: Chad M
authors.initials: CM
authors.lastname: Vezina
authors.forename: Sarah Hicks
authors.initials: SH
authors.lastname: Allgeier
authors.forename: Robert W
authors.initials: RW
authors.lastname: Moore
authors.forename: Tien-Min
authors.initials: TM
authors.lastname: Lin
authors.forename: Jeffrey C
authors.initials: JC
authors.lastname: Bemis
authors.forename: Heather A
authors.initials: HA
authors.lastname: Hardin
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Gasiewicz
authors.forename: Richard E
authors.initials: RE
authors.lastname: Peterson
mesh_terms: D000818:Animals; D001483:Base Sequence; D019521:Body Patterning / Q000187:drug effects*; D017931:DNA Primers; D004305:Dose-Response Relationship, Drug; D005260:Female; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008855:Microscopy, Electron, Scanning; D000072317:Polychlorinated Dibenzodioxins / Q000633:toxicity*; D011247:Pregnancy; D011467:Prostate / Q000187:drug effects* / Q000196:embryology
chemical_list: D017931:DNA Primers; D000072317:Polychlorinated Dibenzodioxins
references.citation: Toxicol Sci. 2003 Nov;76(1):171-81
references.pmid: 12944588
references.citation: Mech Dev. 1998 Apr;73(1):117-23
references.pmid: 9545558
references.citation: Toxicol Appl Pharmacol. 2002 Oct 1;184(1):57-66
references.pmid: 12392969
references.citation: Toxicol Sci. 2003 Dec;76(2):427-36
references.pmid: 14514962
references.citation: Curr Top Dev Biol. 2008;81:1-63
references.pmid: 18023723
references.citation: J Exp Zool. 1978 Aug;205(2):181-93
references.pmid: 681909
references.citation: Development. 2006 May;133(9):1611-24
references.pmid: 16613830
references.citation: Toxicol Appl Pharmacol. 2004 Apr 1;196(1):149-55
references.pmid: 15050416
references.citation: Epithelial Cell Biol. 1993 Apr;2(2):66-78
references.pmid: 8353595
references.citation: Dev Biol. 2003 Sep 1;261(1):39-54
references.pmid: 12941620
references.citation: Semin Cell Dev Biol. 2007 Apr;18(2):237-44
references.pmid: 17336109
references.citation: Differentiation. 2008 Jul;76(6):728-35
references.pmid: 18557758
references.citation: J Urol. 2004 Jul;172(1):365-8
references.pmid: 15201812
references.citation: Toxicol Sci. 2002 May;67(1):63-74
references.pmid: 11961217
references.citation: Toxicol Appl Pharmacol. 1998 Jul;151(1):33-44
references.pmid: 9705885
references.citation: Science. 1993 Jul 9;261(5118):215-8
references.pmid: 8392225
references.citation: Toxicol Appl Pharmacol. 2006 May 1;212(3):200-11
references.pmid: 16125745
references.citation: J Endocrinol. 1987 Jul;114(1):131-7
references.pmid: 3655602
references.citation: Toxicol Sci. 2004 Jun;79(2):360-9
references.pmid: 15056816
references.citation: Toxicol Sci. 2002 Sep;69(1):202-9
references.pmid: 12215675
references.citation: Trends Genet. 1996 Jul;12(7):253-7
references.pmid: 8763496
references.citation: Toxicol Appl Pharmacol. 2007 Oct 1;224(1):29-38
references.pmid: 17655899
references.citation: Curr Top Dev Biol. 2008;81:341-71
references.pmid: 18023734
references.citation: Development. 2002 Apr;129(8):1905-12
references.pmid: 11934856
references.citation: Biol Reprod. 1986 Jun;34(5):961-71
references.pmid: 3730488
references.citation: Toxicol Sci. 2002 Aug;68(2):479-87
references.pmid: 12151645
references.citation: Toxicol Sci. 2002 Dec;70(2):227-37
references.pmid: 12441367
references.citation: J Mammary Gland Biol Neoplasia. 2006 Oct;11(3-4):187-203
references.pmid: 17111222
references.citation: Development. 1999 Aug;126(16):3693-701
references.pmid: 10409514
references.citation: J Toxicol Environ Health A. 2001 Oct 26;64(4):327-42
references.pmid: 11693491
references.citation: Science. 1992 May 22;256(5060):1193-5
references.pmid: 1317062